Participated · Equity · Aug 2026

Kapso builds tooling and infrastructure for developers working with messaging channels, with a particular focus implied on WhatsApp. The company reports rapid usage growth—processing more messages in a single recent hour than it did in the entire month of August 2025—and serves more than 28,000 developers. Andrés Matte is the founder and led the recent $1.4M raise; he also noted he closed the round without a deck. The team has expanded beyond a sole founder to include additional employees following the financing. Public disclosures do not include revenue, valuation, or detailed product roadmaps, though the founder indicated plans and shared more background in a linked write-up.

Participated · Seed · Aug 2026

Fina was founded two years ago to help entrepreneurs manage and grow their finances. The company serves more than 5,000 businesses and reports $2M in ARR with consistent growth. Recently it launched a new vertical three months prior to the announcement that is expanding at 2x month-over-month. Fina plans to use its newly raised capital to launch multiple AI-powered and financial products over the next six months and to accelerate that high-growth vertical. The founders have stated ambitions to scale to $10–20M ARR and to expand across LATAM.

Participated · Seed · Jul 2026

Magnar builds an AI-powered SaaS platform that automates everyday legal workflows, including automated jurisprudence search, AI-generated case summaries, drafting of complaints and legal documents, chatbot-style legal queries and document generation from prompts. The platform leverages foundation models (ChatGPT, Gemini) fine-tuned with local regulatory documentation and holds ISO 27001 and SOC 2 certifications to address security and compliance requirements of law firms. Founded in August 2025 and based in Santiago, Chile, Magnar uses a usage-based pricing model rather than per-seat licenses to lower adoption friction and scale with firm volume. By July 2026 the company reported approximately 25,000 lawyers across Latin America using the product and had expanded to Peru, Colombia, Uruguay, Mexico and launched operations in Argentina. The startup raised US$800,000 in seed funding across two rounds to finance its regional expansion and commercial traction, including strategic investment from Carey. Future plans emphasized rapid regional growth while competing with global and local legaltech players in the Latin American market.

Participated · Series B · Apr 2026

Ray Therapeutics is a Berkeley, California–based clinical-stage biopharmaceutical company developing optogenetic gene therapies to restore vision in patients with severe retinal degenerations. Its lead program, RTx-015, is an optogenetic gene therapy delivered as a single intravitreal injection and is being evaluated in patients with retinitis pigmentosa. The company’s second clinical-stage program, RTx-021, targets retinal bipolar cells and is designed for macular diseases such as Stargardt disease and geographic atrophy (GA AMD). RayTx’s approach delivers a bioengineered, highly light-sensitive protein to targeted retinal cells with the aim of improving visual function regardless of underlying genetic mutation. The company recently received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for RTx-015, and it plans to use recent financing to advance late-stage clinical development and commercial readiness.

Led · Series A · Jan 2026

Poplar Therapeutics, incorporated in 2024 and based in Cambridge, Massachusetts, is focused on creating a new class of anti-IgE therapies that aim to rapidly drive IgE levels toward zero. Its lead candidate, PHB-050, employs a triple-action mechanism to block IgE binding to mast cells, quickly clear circulating IgE, and inhibit further IgE production. The drug is now in a Phase 1 clinical trial targeting food allergy, with data expected to demonstrate safety, pharmacokinetics, and speed of IgE reduction. Management plans to use forthcoming data to guide Phase 2 studies across multiple atopic conditions, including asthma and atopic dermatitis. Poplar estimates that more than seven million patients with atopic diseases have high IgE levels, half of whom with food allergy are poorly served by existing therapies. The company’s total Series A financing now stands at $95 million, providing resources to advance PHB-050 through at least Phase 2 trials.